AUTHOR=Xingmeng Wang , Guohua Dai , Hui Guan , Wulin Gao , Huiwen Qu , Maoxia Fan , Runmin Li , Lili Ren 

TITLE=Clinical efficacy and safety of adjunctive treatment of chronic ischemic heart failure with Qishen Yiqi dropping pills: a systematic review and meta-analysis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=10

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1271608

DOI=10.3389/fcvm.2023.1271608

ISSN=2297-055X

ABSTRACT=<sec><title>Objectives</title><p>Our study was to evaluate the effect of Qishen Yiqi Dropping Pills(QSYQ) on the prognosis of chronic ischemic heart failure(CIHF) and its safety.</p></sec><sec><title>Methods</title><p>Databases including CNKI, Wanfang, VIP, CBM, PubMed, Web of Science, The Cochrane Library and EMbase were searched from their inception to April 2023 to screen relevant randomized controlled trials (RCTs). Primary indicators included readmission rates, rates of major adverse cardiovascular events (MACE), and all-cause mortality rates. The quality of the literature was assessed according to the Cochrane Reviewers' Handbook 5.0 and the Modified Jadad Scale (with a score of 4–7 rated as high quality). Meta-analysis was performed using the meta-package created by R software version 4.2.3, continuous data were compared using SMDs, and dichotomous and ordered data were compared using ORs; and the <italic>I</italic><sup>2</sup> test was used to assess the heterogeneity.</p></sec><sec><title>Results</title><p>Fifty-nine studies out of 1,745 publications were finally included, totalling 6,248 patients. Most studies were poorly designed and had some publication bias, with only 26 high-quality papers (Jadad score ≥4). Meta-analysis showed that the combined application of QSYQ was able to reduce the readmission rate [OR = 0.42, 95% CI (0.33, 0.53), <italic>P</italic> &lt; 0.001], all-cause mortality rate [OR = 0.43, 95% CI (0.27, 0.68), <italic>P</italic> &lt; 0.001], and the incidence of MACE [OR = 0.42, 95% CI (0.31, 0.56), <italic>P</italic> &lt; 0.001]. Also, the treatment method can improve clinical effectiveness [OR = 2.25, 95% CI (1.97, 2.58), <italic>P</italic> &lt; 0.001], increase 6-min walking distance (6MWD) [SMD = 1.87, 95% CI (1.33, 2.41), <italic>P</italic> &lt; 0.0001] and left ventricular ejection fraction (LVEF) [SMD = 1.08, 95% CI (0.83, 1.33), <italic>P</italic> &lt; 0.0001], and decrease the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores [SMD = −2.03, 95% CI (−3.0, −1.07), <italic>P</italic> &lt; 0.0001], BNP levels [SMD = −2.07, 95% CI (−2.81, −1.33), <italic>P</italic> &lt; 0.0001] and NT-ProBNP levels [SMD = −2.77, 95% CI (−4.90, −0.63), <italic>P</italic> &lt; 0.05]. A total of 21 studies (<italic>n</italic> = 2,742) evaluated their adverse effects, of which 13 studies reported no adverse effects and 8 studies reported minor adverse effects.</p></sec><sec><title>Conclusion</title><p>Our results suggest that the combined application of QSYQ can further improve patients' cardiac function and exercise tolerance, improve their quality of life, and ultimately improve patients' prognosis with a favorable safety profile. Nonetheless, limited by the quality and high heterogeneity of the literature, we must be conservative and cautious about the present results.</p></sec><sec><title>Systematic Review Registration</title><p>PROSPERO (CRD42023449251).</p></sec>